Hybrid scanner helps to enhance visibility of skin cancer cells

NewsGuard 100/100 Score

Scientists are reporting development of a substance to enhance the visibility of skin cancer cells during scans with an advanced medical imaging system that combines ultrasound and light. The hybrid scanner could enable doctors to detect melanoma, the most serious form of skin cancer, in its earliest and most curable stages, the report in the monthly journal ACS Nano indicates.

Lihong Wang, Younan Xia, and colleagues point out that early diagnosis is key to improving survival in patients with melanoma. The five-year survival rate for melanoma is about 98 percent if detected early but can be as low as 15 percent when detected at an advanced stage. Existing imaging techniques for early detection of melanoma produce low-quality images, can "see" only a fraction of an inch below the skin, and use potentially harmful radioactive materials. A promising new technique called photoacoustic tomography (PAT) can overcome these problems. The system shoots light into tumors, which slightly heats up the cancer cells and produces high frequency sound waves that provide images of the tumor. But the PAT system lacks an optimal contrast agent that can easily enter skin cancer cells and make them visible.

The scientists developed such an agent by attaching a peptide (one of the building blocks of proteins) that targets skin cancer cells to gold "nanocages." These hollow gold nanoparticles have a box-like shape and are barely 1/50,000th the width of a human hair. When injected into mice with skin cancer, the nanocages improved the image quality of the cancer cells by three-fold compared to nanoparticles lacking the peptide. The gold nanocages also show promise as a way to kill skin cancer cells using heat or anti-cancer drugs, they add.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cancer history raises cardiovascular disease risk in hypertensive patients